// STATE LEGISLATION TRACKER

Arizona HB 2953 — pharmacy board; civil penalties.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Arizona
Bill: HB 2953
Filed: 2026-02-02
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Available metadata only says this is an Arizona bill about the pharmacy board and civil penalties. It does not show peptide-specific language, compounding rules, telehealth changes, scope-of-practice changes, controlled substances, or prescription monitoring changes.

Key Points

No peptide-specific impact is visible from the title or metadata provided.
No clear change to compounded peptide access can be inferred.
No visible effect on off-label prescribing, telehealth, NPs, or naturopaths.

What to Watch For

Note Watch for the actual bill text or official status page before treating this as active policy.

Concern If the penalties apply to compounding pharmacies, it could indirectly affect pharmacy risk and costs.

Note No available metadata links this bill to FDA 503A/503B compounding or controlled substances.

Where the Bill Stands

The provided source reports that OpenStates refetch failed, and no reliable latest action is available from the supplied metadata.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws